CAMK2 Community Voice Shared with the FDA
On May 27, 2026, members of the CAMK2 community participated in a Listening Session with representatives from the U.S. Food and Drug Administration (FDA). This important discussion provided an opportunity for individuals and families affected by CAMK2-related disorders to share their experiences, challenges, priorities, and hopes for the future directly with regulators.
We are grateful to the individuals and families who contributed their perspectives and helped ensure that the voices of the CAMK2 community were heard. These conversations play an important role in increasing awareness of CAMK2-related disorders and helping regulators better understand what matters most to patients and caregivers.
